Mereo BioPharma (MREO) Non-Current Debt (2017 - 2023)

Mereo BioPharma (MREO) has reported Non-Current Debt for 6 consecutive years, with $4.6 million the latest figure, recorded in Q2 2023.

• On a quarterly basis, Non-Current Debt changed N/A year-over-year to $4.6 million in Q2 2023; TTM through Jun 2023 was $4.6 million, a N/A change from a year earlier, with the FY2021 full-year figure at $19.4 million, down 9.03% from the prior year.
• Non-Current Debt was $4.6 million for Q2 2023 at Mereo BioPharma, down from $19.4 million in the prior quarter.
• Over five years, Non-Current Debt peaked at $25.1 million in Q2 2021 and troughed at $4.6 million in Q2 2023.
• A 4-year average of $15.8 million and a median of $18.0 million in 2020 frame the typical range for Non-Current Debt.
• Across the five-year window, Non-Current Debt plunged 63.35% in 2019 and soared 208.54% in 2020, its largest moves.
• Over 4 years, Non-Current Debt stood at $6.9 million in 2019, then soared by 208.54% to $21.3 million in 2020, then decreased by 9.03% to $19.4 million in 2021, then sank by 76.35% to $4.6 million in 2023.
• The last three Non-Current Debt figures came in at $4.6 million (Q2 2023), $19.4 million (Q4 2021), and $25.1 million (Q2 2021), per Business Quant data.